Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress

Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress

NEW YORK November 9, 2017 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing

medicines for patients with rare neurological diseases, today announced financial results for the third quarter ended September 30, 2017 and provided an overview of the company s recent business progress.

We continue to make excellent progress to develop OV101 and TAK-935/OV935 as promising, first-in-class therapeutics for rare neurological disorders with few or no available therapies, said Jeremy Levin, DPhil, MB BChir, chairman and chief executive officer

of Ovid Therapeutics. We plan to announce results from our Phase 1 PK study in adolescents with Angelman syndrome or Fragile X syndrome during the coming weeks, which we believe may pave the way for a broader development strategy with OV101.

In parallel, we continue to enroll patients in the Phase 2 STARS trial in adults with Angelman syndrome as well as our Phase 1b/2a clinical trial of TAK-935/OV935 in adults with rare developmental and/or

epileptic encephalopathies in collaboration with Takeda. We look forward to important milestones throughout the remainder of the year and in 2018 as we continue to execute on our near-term objectives and long-term strategy.

Recent Highlights and Upcoming Milestones

Neurodevelopmental Disorders

TAK-935/OV935 for Developmental and/or Epileptic Encephalopathies

Third Quarter 2017 Financial Results

OV101 (gaboxadol) is believed to be the only delta ( )-selective GABAA receptor agonist in development and the first investigational drug to specifically target the disruption of tonic inhibition that is thought to be the underlying cause of certain

neurodevelopmental disorders. OV101 has been demonstrated in laboratory studies and animal models to selectively activate the -subunit of GABAA

receptors, which are found in the extrasynaptic space (outside of the synapse), and thereby impact neuronal activity through tonic inhibition.

developing OV101 for the treatment of Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. In preclinical studies, it was observed that OV101 improved symptoms of

Angelman syndrome and Fragile X syndrome. To date, gaboxadol has been tested in over 4,000 patients (approximately 950 patient-years of exposure) in several indications, and was observed to have favorable safety and bioavailability profiles.

The FDA granted orphan drug designation for OV101 for the treatment of both Angelman syndrome and Fragile X syndrome. The United States Patent and Trademark

Office has granted Ovid two patents directed to methods of treating Angelman syndrome using OV101. The issued patents expire in 2035, without regulatory extensions.

TAK-935/OV935, which is being studied in rare epilepsies, is a potent, highly-selective,

first-in-class inhibitor of the enzyme CH24H. CH24H is predominantly expressed in the brain, where it plays a central role in cholesterol homeostasis. CH24H converts

cholesterol to 24HC, which then exits the brain into the blood plasma circulation. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature

indicates CH24H is involved in over-activation of the glutamatergic pathway through modulation of the NMDA channel, implying its potential role in central nervous system diseases such as epilepsy. To Ovid s knowledge, TAK-935/OV935 is the only molecule with this mechanism of action in clinical development.

TAK-935/OV935 has been tested in preclinical models to provide data to support the advancement of the drug into human clinical studies in patients suffering from rare epilepsy syndromes. A novel proprietary PET

ligand, developed by Takeda and Molecular Neuroimaging, LLC (MNI), has been used to determine target occupancy of TAK-935/OV935 in the brain. In addition,

TAK-935/OV935 s effect on CH24H enzyme activity in the brain has been assessed by following measurable reductions in the plasma concentration of 24HC.

TAK-935/OV935 has completed four Phase 1 clinical studies, which have assessed tolerability and target engagement at

doses believed to be therapeutically relevant. TAK-935/OV935 is being co-developed by Ovid and Takeda Pharmaceutical Company Limited.

About Ovid Therapeutics

Ovid Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical company using its BoldMedicine approach to develop therapies that transform the

lives of patients with rare neurological disorders. Ovid s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with

Angelman syndrome and a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies and has

initiated a Phase 1b/2a trial of OV935.

For more information on Ovid, please visit http://www.ovidrx.com/.

Forward-Looking Statements

This press release includes

certain disclosures that contain forward-looking statements, including, without limitation, statements regarding progress, timing, scope and results of clinical trials for Ovid s product candidates, the reporting of clinical data

regarding Ovid s product candidates, and the study of the role of 24-S-hydroxycholesterol (24HC) as a plasma-based biomarker. You can identify forward-looking

statements because they contain words such as will, believes and expects. Forward-looking statements are based on Ovid s current expectations and assumptions. Because forward-looking statements relate to the

future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances

of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid s filings with the Securities and Exchange Commission, including its Quarterly

Report on Form 10-Q for the quarter ended September 30, 2017, under the caption Risk Factors. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect

any change in expectations, even as new information becomes available.

Steve Klass, 212-213-0006

Pure Communications, Inc.

Katie Engleman, 910-509-3977

OVID THERAPEUTICS INC.

Condensed Statements of Operations and Comprehensive Loss (unaudited)

OVID THERAPEUTICS INC.

Selected Condensed Balance Sheet Data (unaudited)